Meticulous Research®—a leading global market research company, published a research report titled Immunohistochemistry (IHC) Market Size, Share, Forecast, & Trends Analysis by Offering (Reagents [Fixation, Buffer, Blocking, Antibodies], Kits, Equipment [Staining, Imaging] Method (ABC, CSA, PAP) Process, Application, End User—Global Forecast to 2032.
According to this latest publication from Meticulous Research®, the global immunohistochemistry market is estimated to reach $4.08 billion by 2032 at a CAGR of 7.2% from 2025 to 2031.The growth of this market can be attributed to various factors, such as the rising prevalence of chronic diseases coupled with the increasing geriatric population, increasing focus on rare diseases, rising awareness regarding early disease diagnosis, increasing R&D expenditure, growing demand for drug discovery & development, rising prevalence of infectious diseases, and the rise in healthcare expenditure. Furthermore, increasing inclination towards personalized medicine, advancements in genomics and proteomics, and increasing automation in immunohistochemistry are expected to offer growth opportunities. However, stringent technical requirements, regulatory processes, and the availability of alternative technology are major hindrances to the market’s growth.
Key Players
The key players operating in the global immunohistochemistry market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Eagle Biosciences, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S), Cell Signaling Technology, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio SB Inc. (U.S.), Biocare Medical, LLC. (U.S.), Bio-Genex Laboratories (U.S.), CANDOR Bioscience GmbH (Germany), and Innovex Biosciences Inc. (U.S.).
Key Factors Driving Immunohistochemistry Market Growth:
One of the primary drivers behind the expanding IHC market is the rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and infectious diseases. With cancer anticipated to remain a leading cause of mortality—causing nearly 10 million deaths annually according to WHO—there is a greater demand for sophisticated diagnostic approaches. IHC plays a pivotal role by enabling accurate categorization and prognosis of tumors based on protein markers, accelerating precise treatment decisions.
In parallel, the aging global population is fueling an increased incidence of age-related illnesses, thereby magnifying the need for advanced laboratory solutions such as IHC. Societal changes, including increased tobacco and alcohol consumption, sedentary lifestyles, and poor dietary habits, contribute significantly to the growing burden of chronic diseases, further driving market adoption.
Additionally, pharmaceutical and biotechnology industries are ramping up R&D expenditures to propel discovery and development of new drugs, leveraging IHC as a critical research tool. The European Union, for example, boosted R&D spending to USD 374.1 billion in 2022, reflecting mounting investments across regions such as India and China. This investment is expected to bolster the demand for innovative IHC products and solutions in the coming years.
Most Recent Global Market Size Estimates and Forecasts:
The global immunohistochemistry market size reached USD 2.8 billion in 2024, with projections to soar to approximately USD 4.08 billion by 2032, registering a Compound Annual Growth Rate (CAGR) of 7.2% from 2025 to 2032. Some forecasts suggest even higher growth, with estimates reaching up to USD 5.73 billion by 2035 at a 6.7% CAGR, depending on methodology and segment focus. This expansion is attributed to rising demand for personalized medicine, increasing healthcare expenditures, and technological innovations in diagnostics.
When segmenting by product offering, consumables—especially reagents and kits—are expected to dominate, comprising nearly 68.4% of the market share by 2025. Method-wise, the avidin-biotin complex technique will continue leading due to its high sensitivity, reduced assay time, and efficient detection capabilities.
Market Opportunities for Players and New Entrants:
For established companies, opportunities abound in developing AI-driven IHC technologies that streamline workflow, enhance analysis, and standardize reporting—key for large-scale clinical adoption. Recent launches, such as Indica Labs’ Breast IHC AI and Visiopharm A/S’s Ki67 algorithm, are revolutionizing biomarker quantification and tumor cell classification in cancer diagnostics.
New entrants should leverage the growing focus on personalized medicine and capitalize on the shift towards multiplexed diagnostic platforms. Expanding product portfolios to cover not only oncology but also neurology, infectious disease, and veterinary diagnostics can open lucrative, under-served markets. Strategic partnerships with research organizations, local hospitals, and academic institutions are essential for market access and visibility in regions like Asia Pacific, where healthcare transformation is rapid.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5967
Key questions answered in the report:
- Which are the high-growth market segments in terms of offerings, method, application, end user, and region/country?
- What was the historical market size for immunohistochemistry globally?
- What are the market forecasts and estimates for the period 2025–2032?
- What are the major drivers, restraints, challenges, opportunities, and trends in the immunohistochemistry market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
0 comment